tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

REGN Stock Latest News

Regeneron’s Linvoseltamab Trial: A Potential Game-Changer in Multiple Myeloma Treatment
Company AnnouncementsRegeneron’s Linvoseltamab Trial: A Potential Game-Changer in Multiple Myeloma Treatment
23h ago
REGN
Regeneron’s Gene-Silencing Study for MASH: A Potential Market Game-Changer
PremiumCompany Announcements
Regeneron’s Gene-Silencing Study for MASH: A Potential Market Game-Changer
23h ago
REGN
Regeneron’s Innovative Approach: Linvoseltamab in Multiple Myeloma Study
PremiumCompany Announcements
Regeneron’s Innovative Approach: Linvoseltamab in Multiple Myeloma Study
23h ago
REGN
Regeneron’s New NSCLC Study: Potential Game-Changer in Cancer Treatment?
PremiumCompany Announcements
Regeneron’s New NSCLC Study: Potential Game-Changer in Cancer Treatment?
23h ago
REGN
Regeneron’s Aflibercept Study: A Closer Look at Retinal Vasculitis Incidence
PremiumCompany Announcements
Regeneron’s Aflibercept Study: A Closer Look at Retinal Vasculitis Incidence
23h ago
REGN
Regeneron and Sanofi’s Phase 3 Trial for Itepekimab: A Potential Game-Changer in Chronic Rhinosinusitis Treatment
PremiumCompany AnnouncementsRegeneron and Sanofi’s Phase 3 Trial for Itepekimab: A Potential Game-Changer in Chronic Rhinosinusitis Treatment
23h ago
SNY
REGN
Regeneron and Sanofi’s Dupilumab Study: A Potential Game-Changer for Pediatric Prurigo Nodularis
Premium
Company Announcements
Regeneron and Sanofi’s Dupilumab Study: A Potential Game-Changer for Pediatric Prurigo Nodularis
23h ago
SNY
REGN
Regeneron and Sanofi’s Dupilumab Study: Long-Term Safety Insights for Pediatric Atopic Dermatitis
Premium
Company Announcements
Regeneron and Sanofi’s Dupilumab Study: Long-Term Safety Insights for Pediatric Atopic Dermatitis
23h ago
SNY
REGN
Regeneron and Sanofi’s Phase 3 Study on Itepekimab: A Potential Game-Changer for Chronic Rhinosinusitis Treatment
PremiumCompany Announcements
Regeneron and Sanofi’s Phase 3 Study on Itepekimab: A Potential Game-Changer for Chronic Rhinosinusitis Treatment
24h ago
SNY
REGN
QQQ ETF News, 6/26/2025
PremiumMarket News
QQQ ETF News, 6/26/2025
1d ago
APP
QQQ
Regeneron’s Heart Failure Study: A Potential Game-Changer in Cardiovascular Treatment
PremiumCompany Announcements
Regeneron’s Heart Failure Study: A Potential Game-Changer in Cardiovascular Treatment
2d ago
REGN
Regeneron and Sanofi’s Dupilumab Study: A Potential Breakthrough in Pediatric Asthma Treatment
PremiumCompany Announcements
Regeneron and Sanofi’s Dupilumab Study: A Potential Breakthrough in Pediatric Asthma Treatment
2d ago
SNY
REGN
Regeneron’s Promising Phase 3 Study on Odronextamab for Follicular Lymphoma
PremiumCompany AnnouncementsRegeneron’s Promising Phase 3 Study on Odronextamab for Follicular Lymphoma
2d ago
REGN
Regeneron’s Latest Clinical Study: A Potential Game-Changer in Cancer Treatment
Premium
Company Announcements
Regeneron’s Latest Clinical Study: A Potential Game-Changer in Cancer Treatment
2d ago
REGN
Regeneron’s Promising Phase 3 Study on Cemiplimab for Skin Cancer
Premium
Company Announcements
Regeneron’s Promising Phase 3 Study on Cemiplimab for Skin Cancer
2d ago
REGN
Regeneron’s Phase 3 Study: A Potential Game-Changer in Lymphoma Treatment
PremiumCompany Announcements
Regeneron’s Phase 3 Study: A Potential Game-Changer in Lymphoma Treatment
2d ago
REGN
Regeneron’s REGN7544: A Promising Phase 2 Study for Sepsis-Induced Hypotension
PremiumCompany Announcements
Regeneron’s REGN7544: A Promising Phase 2 Study for Sepsis-Induced Hypotension
2d ago
REGN
Regeneron’s Aflibercept Study: A Closer Look at Retinal Vasculitis Incidence
PremiumCompany Announcements
Regeneron’s Aflibercept Study: A Closer Look at Retinal Vasculitis Incidence
3d ago
REGN
Regeneron’s Linvoseltamab Study: A Potential Game-Changer for Multiple Myeloma Treatment
PremiumCompany Announcements
Regeneron’s Linvoseltamab Study: A Potential Game-Changer for Multiple Myeloma Treatment
3d ago
REGN
Regeneron’s Gene Silencing Study Targets Chronic Liver Disease
PremiumCompany AnnouncementsRegeneron’s Gene Silencing Study Targets Chronic Liver Disease
3d ago
REGN
Regeneron’s Linvoseltamab Study: A Potential Game-Changer in Multiple Myeloma Treatment
Premium
Company Announcements
Regeneron’s Linvoseltamab Study: A Potential Game-Changer in Multiple Myeloma Treatment
3d ago
REGN
Regeneron’s Promising Phase 2 NSCLC Trial: A Potential Game Changer?
Premium
Company Announcements
Regeneron’s Promising Phase 2 NSCLC Trial: A Potential Game Changer?
3d ago
REGN

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >